Merck Exceeds Third-Quarter Forecasts on Keytruda, Gardasil Results
Merck exceeded forecasts for the third quarter, citing strong results for Keytruda and Gardasil. The body specifically mentions Keytruda.
Related stories
Iron Ore Slips on Weak Fundamentals
Iron ore futures fell below CNY 680 per ton, sliding toward four-year lows as rising port inventories, subdued steel mill profitability and sluggish demand continued to pressure pr
L impact | EARNINGS | Oct 30, 2026, 07:20 AM UTC
Airtel Africa H1 Revenue Rises Across Regions and Segments
M impact | EARNINGS | Oct 30, 2026, 07:17 AM UTC
Amazon Reports Higher Capex and Negative Cash Flow in Q3
Amazon reported a jump in capital expenditures and negative cash flow in the third quarter.
M impact | EARNINGS | Oct 30, 2026, 07:08 AM UTC
BP Reports Net Profit Above Expectations
BP reported net profit and said it exceeded expectations.
M impact | EARNINGS | Oct 30, 2026, 07:07 AM UTC
BP posts net income of $8.46 billion
BP reported net income of $8.46 billion.
M impact | EARNINGS | Oct 30, 2026, 07:07 AM UTC
AstraZeneca 3Q Farxiga Sales Fall 25% at Constant Currency
Farxiga sales were $1.605 billion in the third quarter, down 25% at constant currency.
M impact | EARNINGS | Oct 30, 2026, 07:06 AM UTC